Therapy Detail

Therapy Name Tremelimumab
Therapy Description

Tremelimumab binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tremelimumab CP-675,206 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 Tremelimumab binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02571725 Phase Ib/II Tremelimumab Olaparib PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Recruiting
NCT02551159 Phase III Cisplatin Durvalumab Cetuximab + Carboplatin + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Active, not recruiting
NCT01853618 Phase I Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer Active, not recruiting
NCT02311361 Phase I Durvalumab Tremelimumab Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Recruiting
NCT02626130 Phase I Tremelimumab Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC) Active, not recruiting
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed
NCT02301130 Phase I Mogamulizumab Durvalumab Tremelimumab Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors Completed
NCT02643303 Phase Ib/II MEDI4736 + poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT03007407 Phase II Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Recruiting
NCT02319044 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02179671 Phase II Selumetinib + Docetaxel Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
NCT02141542 Phase I Tremelimumab MEDI3617 Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Active, not recruiting
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Recruiting
NCT02485990 Phase Ib/II Olaparib Tremelimumab Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) Recruiting
NCT02205333 Phase Ib/II Rituximab MEDI6469 Tremelimumab Durvalumab A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies Terminated
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Recruiting
NCT02453282 Phase III Durvalumab Gemcitabine + Cisplatin Paclitaxel + Carboplatin Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Active, not recruiting
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting
NCT03557918 Phase II Tremelimumab Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Recruiting
NCT02535078 Phase Ib/II Durvalumab IMCgp100 Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Active, not recruiting
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting
NCT02558894 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed
NCT02563925 Phase I Tremelimumab Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Active, not recruiting
NCT02340975 Phase Ib/II Durvalumab Tremelimumab A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Active, not recruiting
NCT02352948 Phase III Durvalumab Erlotinib + Gemcitabine + Vinorelbine Durvalumab + Tremelimumab Tremelimumab A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Active, not recruiting